Skip to main content

Table 1 PICOS statement for the inclusion and exclusion criteria

From: Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis

 InclusionExclusion
Study populationPatients with high-volume metastatic hormone-sensitive prostate cancer, regardless of age, sex, ethnic group or disease statusAny not listed in the inclusion criteria
InterventionDocetaxel + ADTAny not listed in the inclusion criteria
ComparatorAbiraterone + prednisone + ADT
ADT alone
Any not listed in the inclusion criteria
Outcome measuresClinical efficacy outcomes Safety outcomesAny not listed in the inclusion criteria
Study designRandomised clinical trials (RCTs)Editorials OR Notes OR Comments OR Letters OR Case reports OR Pharmacokinetic studies OR Epidemiology studies
RestrictionsFull-text published manuscripts in English or Chinese
Year limitation: up to Nov 2017
Duplicates
Not full-text published manuscripts Non-English or non-Chinese studies